Daxor Corporation

9.09-0.0600-0.66%Vol 24.67K1Y Perf -49.05%
Jul 30th, 2021 14:09 DELAYED
BID0.0000 ASK9.85
Open9.20 Previous Close9.15
Pre-Market- After-Market-
 - -  - -%
Target Price
21.50 
Analyst Rating
Moderate Buy 2.00
Potential %
136.52 
Finscreener Ranking
★★★ —    -
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★+ —    -
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Market Cap36.67M 
Earnings Rating
Buy
Price Range Ratio 52W %
5.17 
Earnings Date
28th Mar 2012

Today's Price Range

8.9910.14

52W Range

8.5818.45

5 Year PE Ratio Range

-98.1027.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-8.73%
1 Month
-14.25%
3 Months
-6.48%
6 Months
-32.67%
1 Year
-49.05%
3 Years
71.51%
5 Years
12.50%
10 Years
-3.45%

TickerPriceChg.Chg.%
DXR9.09-0.0600-0.66
AAPL145.860.22000.15
GOOG2 704.42-26.3900-0.97
MSFT284.91-1.5900-0.55
XOM57.57-1.3600-2.31
WFC45.94-0.5600-1.20
JNJ172.200.02000.01
FB356.30-2.0200-0.56
GE12.95-0.3400-2.56
JPM151.78-1.2200-0.80
Earnings HistoryEstimateReportedSurprise %
Q04 2011--0.35-
Q03 2011--0.99-
Q02 2011--0.04-
Q01 2011--0.31-
Q04 2010-0.53-
Q03 2010-0.62-
Q02 2010-0.04-
Q01 2010--0.02-
Earnings Per EndEstimateRevision %Trend
12/2007 QR---
3/2008 QR---
12/2020 FY0.150.00-
12/2021 FY0.400.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume24.67K
Shares Outstanding4.03M
Trades Count383
Dollar Volume17.56K
Avg. Volume18.83K
Avg. Weekly Volume20.35K
Avg. Monthly Volume44.74K
Avg. Quarterly Volume30.73K

Daxor Corporation (AMEX: DXR) stock closed at 9.09 per share at the end of the most recent trading day (a -0.66% change compared to the prior day closing price) with a volume of 24.67K shares and market capitalization of 36.67M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 750 people. Daxor Corporation CEO is Michael Feldschuh.

The one-year performance of Daxor Corporation stock is -49.05%, while year-to-date (YTD) performance is -27.28%. DXR stock has a five-year performance of 12.5%. Its 52-week range is between 8.58 and 18.45, which gives DXR stock a 52-week price range ratio of 5.17%

Daxor Corporation currently has a PE ratio of -35.60, a price-to-book (PB) ratio of 2.56, a price-to-sale (PS) ratio of 17.39, a price to cashflow ratio of 26.90, a PEG ratio of 2.32, a ROA of -10.65%, a ROC of -% and a ROE of -11.53%. The company’s profit margin is 85.44%, its EBITDA margin is -%, and its revenue ttm is $2.24 Million , which makes it $0.55 revenue per share.

Of the last four earnings reports from Daxor Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Daxor Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Daxor Corporation is Moderate Buy (2), with a target price of $21.5, which is +136.52% compared to the current price. The earnings rating for Daxor Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Daxor Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Daxor Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 31.63, ATR14 : 0.94, CCI20 : -82.35, Chaikin Money Flow : -0.31, MACD : -0.44, Money Flow Index : 78.67, ROC : -13.01, RSI : 37.52, STOCH (14,3) : 9.53, STOCH RSI : 0.18, UO : 26.76, Williams %R : -90.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Daxor Corporation in the last 12-months were: Robert J. Michel (Buy at a value of $10 250)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (33.33 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
1 (33.33 %)
1 (33.33 %)
Hold
1 (50.00 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Daxor Corporation

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

CEO: Michael Feldschuh

Telephone: +1 212 330-8500

Address: 350 Fifth Avenue, New York 10118, NY, US

Number of employees: 750

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

News

Stocktwits